| Objective: In order to find whether the researched results had been published has the publication bias, and provide the scientific support for early diagnosis of the hepatocarcinoma, we use the meta-analysis to research the circulating miRNAs’ diagnostic value for hepatocarcinoma.Methods: Using the foreign databases such PubMed, Embase, Cochrane and the domestic CNKI, Wanfang to comprehensively collect the literatures before July 2012.At last, we collected eight literatures that must accord with the called for inclusion and exclusion criterions into the research. In the research, we use the Meta-Disc(version 1.4)to analyze the materials, and test the heterogeneity by using Cochran-Q and I2 in the base of Chi-square. Besides, we selected the random-effects models to count the merged effect values that include the merged sensitivity, specificity, positive likelihood ratio,negative likelihood ratio and diagnostic odds ratio. Meanwhile we evaluated the miRNAs’ overall diagnostic ability by summary receiver operating characteristic curves(sROC). Stata11.0 was used to evaluate the publication bias. Result: The miRNAs’ merged sensitivity was 86%(95% CI: 0.84-0.88), specificity was 89%(95%CI :0.87-0.91), positive likelihood ratio was 6.32(95% CI: 3.62-11.01), negative likelihood ratio was 0.18(95% CI:0.11-0.28), diagnostic odds ratio was 39.52(95% CI:16.83-92.77). At last the AUC was 0.93 with Q value of 0.86. These literatures had been published hadn’t find the publication bias. Conclusion : Circulating miRNAs is a potential biomarker in the diagnosis of hepatocarcinoma. It’s very valuable as a new biomarker to find the early hepatocarcinoma. |
PDF Full Text Request